Rowlandmiller & PARTNERS.ADV Reduces Stake in Baxter International Inc. (NYSE:BAX)

Rowlandmiller & PARTNERS.ADV lowered its position in Baxter International Inc. (NYSE:BAX) by 28.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 4,067 shares of the medical instruments supplier’s stock after selling 1,613 shares during the period. Rowlandmiller & PARTNERS.ADV’s holdings in Baxter International were worth $119,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Fortitude Family Office LLC purchased a new stake in Baxter International in the 3rd quarter worth approximately $38,000. LRI Investments LLC boosted its position in Baxter International by 60.8% in the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 590 shares in the last quarter. Bruce G. Allen Investments LLC boosted its position in Baxter International by 247.3% in the 4th quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 1,867 shares in the last quarter. CKW Financial Group boosted its position in Baxter International by 19.3% in the 4th quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier’s stock worth $77,000 after purchasing an additional 425 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Baxter International by 23.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,519 shares of the medical instruments supplier’s stock worth $96,000 after purchasing an additional 475 shares in the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Stock Up 1.3 %

NYSE BAX opened at $33.87 on Monday. The business has a fifty day moving average price of $30.65 and a 200 day moving average price of $34.10. Baxter International Inc. has a one year low of $28.33 and a one year high of $44.01. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. The company has a market cap of $17.29 billion, a P/E ratio of -26.46, a P/E/G ratio of 10.62 and a beta of 0.61.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, beating the consensus estimate of $0.52 by $0.06. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%. The firm had revenue of $2.75 billion during the quarter, compared to the consensus estimate of $2.67 billion. Research analysts anticipate that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Friday, February 28th will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 2.01%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International’s payout ratio is currently -53.13%.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Citigroup lowered their price objective on Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. JPMorgan Chase & Co. lowered their price objective on Baxter International from $38.00 to $36.00 and set a “neutral” rating on the stock in a research report on Friday. Barclays began coverage on Baxter International in a research report on Thursday. They issued an “overweight” rating and a $39.00 price objective on the stock. Stifel Nicolaus reduced their target price on Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Finally, StockNews.com downgraded Baxter International from a “buy” rating to a “hold” rating in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $38.80.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.